The compound formulation inhibits ovarian cancer cell invasion and metastasis by down-regulating the protein expression of HIF-α, MMP-2, MMP-9, and E-cadherin, demonstrating significantly in vivo pharmacodynamic effects. Here, CDH1 is linked to ovarian carcinoma.